EUVIMEDEUVIMED entdecken
Crossref

Saroglitazar, a Dual PPAR α/γ Agonist, Improves Atherogenic Dyslipidemia in Patients With Non-Cirrhotic Nonalcoholic Fatty Liver Disease: A Pooled Analysis

Mohammad Shadab Siddiqui, Deven Parmar, Farheen Sheikh, Shiv Kumar Sarin, Laura Cisneros, Samer Gawrieh, Taufik Momin, Ajay Duseja, Arun J Sanyal

Clinical Gastroenterology and Hepatology · 2023-09 · 21 (10) · 2597-2605.e2

DOI: 10.1016/j.cgh.2023.01.018 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Gastroenterology and Hepatology, 2023-09. Verfasst von Mohammad Shadab Siddiqui und 8 weiteren Autor:innen. Beteiligte Einrichtung: Virginia Commonwealth University, Richmond, Virginia. Electronic address: mohammad.siddiqui@vcuhealth.org. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Diabetes Mellitus, Type 2, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Dyslipidemias. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Novartis, Gilead Sciences, Novartis Pharmaceuticals Corporation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND & AIMS: Cardiovascular disease is the leading cause of mortality in nonalcoholic fatty liver disease (NAFLD). The aim of this study was to evaluate the effects of saroglitazar, a dual peroxisome proliferator-activated receptor α/γ agonist, on serum lipids in patients with NAFLD. METHODS: A total of 221 patients (saroglitazar, 130; placebo, 91) with NAFLD from phase 2 and 3 double-blinded placebo-controlled randomized clinical trials were pooled to assess the impact of saroglitazar magnesium 4 mg on traditional lipids, very low density lipoprotein cholesterol (VLDL-C), and small dense LDL-C (sdLDL-C). Change from baseline in lipid parameters was performed by using analysis of covariance including treatment as fixed effect and baseline value, diabetes, hypertension, and statin use as covariates. RESULTS: Treatment with saroglitazar significantly improved total cholesterol (-17 mg/dL, 95% confidence interval [CI], -24 to 9; P < .001), triglyceride (-45 mg/dL, 95% CI, -60 to 31; P < .001), low-density lipoprotein cholesterol (-8 mg/dL, 95% CI, -15 to -1; P = .01), and VLDL-C (-8 mg/dL, -14 to -3; P < .001). Saroglitazar improved serum lipids as early as 4-6 weeks of initiation of therapy, and these effects persisted for duration of therapy. Saroglitazar also improved the highly atherogenic sdLDL-C (-10 mg/dL, -17 to -2; P = .01). In subgroup analysis of patients with either diabetes or hypertension, saroglitazar significantly improved serum lipids. CONCLUSIONS: Saroglitazar improved the serum atherogenic lipoprotein profile in patients with NAFLD, irrespective of comorbid conditions and statin use. Saroglitazar has the potential to not only positively affect liver disease but also reduce cardiovascular risk in patients with NAFLD. (Trials registrations: CTRI 2015/10/006236, CTRI 173300410A0106, NCT03863574, and NCT03061721).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Non-alcoholic Fatty Liver DiseaseDiabetes Mellitus, Type 2Hydroxymethylglutaryl-CoA Reductase InhibitorsDyslipidemiasHypertensionHumansPPAR alphaPPAR-gamma AgonistsTriglyceridesCholesterolPhenylpropionatesPyrroles

Stichwörter der Autor:innen

Cardiovascular DiseaseLipidsNonalcoholic SteatohepatitisSaroglitazarSmall Dense LDL

Substanzen

PPAR alphaHydroxymethylglutaryl-CoA Reductase InhibitorsPPAR-gamma AgonistsTriglyceridesCholesterolsaroglitazarPhenylpropionatesPyrroles

Autor:innen und Institutionen

  • Virginia Commonwealth University, Richmond, Virginia. Electronic address: mohammad.siddiqui@vcuhealth.org.
  • Zydus Therapeutics Inc USA, Pennington, NJ. Electronic address: dparmar@zydustherapeutics.com.
  • Zydus Therapeutics Inc USA, Pennington, NJ.
  • Department of Hepatology, Institute of Liver & Biliary Sciences, New Delhi, India.
  • Christus Muguerza Alta Especialidad, Monterrey, Mexico.
  • Indiana University School of Medicine, Indianapolis, Indiana.

Förderung

  • Novartis
  • Gilead Sciences
  • Novartis Pharmaceuticals Corporation

Zitieren

APA

Siddiqui, M. S., Parmar, D., Sheikh, F., Sarin, S. K., Cisneros, L., Gawrieh, S., Momin, T., Duseja, A., & Sanyal, A. J. (2023). Saroglitazar, a Dual PPAR α/γ Agonist, Improves Atherogenic Dyslipidemia in Patients With Non-Cirrhotic Nonalcoholic Fatty Liver Disease: A Pooled Analysis. Clinical Gastroenterology and Hepatology, 21(10), 2597-2605.e2. https://doi.org/10.1016/j.cgh.2023.01.018

Vancouver

Siddiqui MS, Parmar D, Sheikh F, Sarin SK, Cisneros L, Gawrieh S, et al. Saroglitazar, a Dual PPAR α/γ Agonist, Improves Atherogenic Dyslipidemia in Patients With Non-Cirrhotic Nonalcoholic Fatty Liver Disease: A Pooled Analysis. Clinical Gastroenterology and Hepatology. 2023;21(10):2597-2605.e2. doi:10.1016/j.cgh.2023.01.018

BibTeX
@article{Siddiqui2023,
  author = {Siddiqui, Mohammad Shadab and Parmar, Deven and Sheikh, Farheen and Sarin, Shiv Kumar and Cisneros, Laura and Gawrieh, Samer and Momin, Taufik and Duseja, Ajay and Sanyal, Arun J},
  title = {Saroglitazar, a Dual PPAR α/γ Agonist, Improves Atherogenic Dyslipidemia in Patients With Non-Cirrhotic Nonalcoholic Fatty Liver Disease: A Pooled Analysis},
  journal = {Clinical Gastroenterology and Hepatology},
  year = {2023},
  volume = {21},
  number = {10},
  pages = {2597--2605.e2},
  doi = {10.1016/j.cgh.2023.01.018}
}
Kostenlos starten →